GOVX - Earnings announcements

Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available

Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;Gedeptin® to advance into expanded Phase 2 clinical trial with activation in the first half of 2025 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developin

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, July 30, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.  Conference Call DetailsDomestic: (800) 715-9871International: +1 (646) 307-1963Conference ID: 3852178Webcast:  https://edge.media-server.com/mmc

Progress across the pipeline in multiple clinical trials, includingPhase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, andmulticenter Phase 1/2 study of Gedeptin®, targeting advanced head and neck cancer Catalyst-rich 2024 with data readouts planned throughout the year Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023. "2023 marked an

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report 2023 financial results on Thursday, February 29, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Dial-in numbers: Domestic:          (800) 715-9871International:    +1 (646) 307-1963Conference ID:  3926207 Webcast:A

Significant Progress towards data milestones in Phase 2 Program of GEO-CM04S1, Next-generation COVID-19 vaccine Gedeptin® clinical data from Phase 1/2 study presented at AACR-AHNS Head and Neck Cancer Conference showing safe administration and tumor reduction Multi-Product License Secured for ProBioGen's AGE1.CR.pIX® suspension cell line to enhance manufacturing capabilities of MVA-based vaccine portfolio Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announc

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Dial-in numbers:Domestic:                    800-715-9871International:                646-307-1963Conference ID:

GeoVax to Host Second Quarter 2023 Conference Call at 4:30 PM ET ATLANTA, GA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report second quarter 2023 financial results on Wednesday, August 9, 2023, after the market closes. Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management's prepared remarks, there will be a Q&A period for analysts and others. Wednesd

ATLANTA, GA, April 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the market closes. Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management's prepared remarks, there will be a Q&A period for analysts and others. Thursday, May 4, 2023, 4:30 PM ETDomestic:                800-715-9871International:          646-307-1963C

Company Expands Ongoing Clinical Trials and theBreadth and Capacity of Its Novel Vaccine Platform Technology ATLANTA, GA, March 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2022. GeoVax's leadership will host a live conference call and webcast at 4:30 p.m. Eastern Time today, March 23, 2023, to discuss financial results and provide a general business update. Details are provided below. 2022 CLINICAL TRIAL PROGRESS AND OP

Conference call to be held Thursday, March 23, at 4:30 p.m. Eastern Time ATLANTA, GA, March 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report 2022 financial results on Thursday, March 23, 2023 after the market closes. Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management's prepared remarks, there will be a Q&A period for analysts and others. Thursday, March 23, 2023, 4:30 PM ET

Phase 2 Clinical Trials Advance for COVID-19 and Immuno-Oncology Company Secures Rights to NIH-MVA for Protection Against Monkeypox and Smallpox ATLANTA, GA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results for the third quarter ended September 30, 2022. GeoVax's management will host a live conference call and webcast at 4:30 p.m. EST on Wednesday, November 9, 2022, to provide a general business update and discuss financial results. Further details are provided below. THIRD QUARTER 2022 DEVELOPMENTS &

ATLANTA, GA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases, announced today that it will report third quarter 2022 financial results after the market close on Wednesday, November 9, 2022. Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management's prepared remarks, there will be a Q&A period for analysts and others. Wednesday, November 9, 2022, 4:30 PM EST Domestic: 877-269-7756 International: 201-689-7817

Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology Evaluation of Company's Vaccine Platform Against Monkeypox Underway ATLANTA, GA, Aug. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced its financial results for the quarter ended June 30, 2022. GeoVax's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time on Wednesday, August 3 to provide a general business update and discuss financial results. Details are provided further below. Six Month 2022 Highlights COVID-19 VACCINE DEV

Conference Call to be Held Wednesday, August 3, at 4:30 p.m. Eastern Time ATLANTA, GA, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report second quarter 2022 financial results on Wednesday, August 3, 2022 after the market closes. Management will host a conference call at 4:30 p.m. ET on Wednesday, August 3, 2022 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. Participants are asked to pre-register for th

Company Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology  ATLANTA, GA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced its financial results for the three months ended March 31, 2022. GeoVax's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time on Wednesday, April 27 to discuss financial results and provide a general business update. Details are provided further below. First Quarter 2022 Highlights Phase 2 Trials – GEO-CM04S1 – GEO-CM04S1 is being

Conference call to be held Wednesday, April 27, at 4:30 p.m. Eastern Time ATLANTA, GA, April 19, 2022 (GLOBE NEWSWIRE) --  via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report first quarter 2022 financial results on Wednesday, April 27, 2022 after the market closes. Management will host a conference call at 4:30 p.m. ET on Wednesday, April 27, 2022 to review financial results and provide an update on corporate developments.  Following management's formal remarks, there will be a question-and-answer session. Participants are asked to pre-register

Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology  ATLANTA, GA, March 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced its financial results for the year ended December 31, 2021 and provided an update on product development programs.  GeoVax's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time on Wednesday, March 9 to discuss financial results and provide a general business update. Details are provided further below. Two Phase 2 Clinical Trials Underway for SARS-CoV-2

Conference call to be held Wednesday, March 9, at 4:30 p.m. Eastern Time Atlanta, GA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report 2021 financial results on Wednesday, March 9, 2022 after the market closes. Management will host a conference call at 4:30 p.m. ET on Wednesday, March 9, 2022 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. Participants are asked to pre-register for the call via th

The GeoVax Multi-antigenic MVA-VLP Approach Designed to Provide a Stronger, Broader Protection Atlanta, GA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing human immunotherapies and vaccines against cancer and infectious diseases, today announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No. 16/648,693 titled "Compositions and Methods for Generating an Immune Response to Treat or Prevent Malaria." In general, the claims to be granted in the patent cover GeoVax's modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite. Glob

Progress in Clinical Development of COVID-19 and Immuno-Oncology Programs ATLANTA, GA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced its financial results for the quarter ended September 30, 2021 and provided a corporate update. GeoVax's management will host a live conference call and webcast today at 4:30 p.m. Eastern Standard Time to discuss financial results and provide a general business update. Details are provided below. Recent Developments On November 9, GeoVax announc

Phase 2 Vaccine Designed to Enhance Response for Immunocompromised Patients  Complements GeoVax's Pan-Coronavirus Vaccine Program ATLANTA, GA and DUARTE, CA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that it has entered into an exclusive license agreement with City of Hope, a world-renowned cancer research and treatment organization. The agreement grants GeoVax exclusive rights to further develop and commercialize a multi-antigenic SARS-CoV-2 investigational vaccine, developed at City of Hope for immunocompromised patients, whic

Conference call to be held Thursday, November 11, at 4:30 p.m. Eastern Time ATLANTA, GA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX) ("GeoVax" or the "Company"), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report third quarter 2021 financial results on Thursday, November 11, 2021 after the market closes. Management will host a conference call at 4:30 p.m. ET on Thursday, November 11, 2021 to review financial results and provide an update on corporate developments.  Following management's formal remarks, there will be a question-and-answer session. Part

Single-dose of GEO-EM01 Provided 100% Protection in Lethal Challenge Evaluation Atlanta, GA, Oct. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 15/543,139 entitled "Replication-Deficient Modified Vaccinia Ankara (MVA) Expressing Ebola Virus Glycoprotein (GP) and Matrix Protein (VP40)." GeoVax has demonstrated that a single intramuscular (IM) dose of its vaccine candidate, GEO-EM01, provided 100% protection in rhesus macaques cha

License of Gedeptin® Adds Orphan Drug Clinical Program for Treatment of Advanced Head and Neck Cancers ATLANTA, GA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that it has entered into an Assignment and License Agreement (the "License") with PNP Therapeutics, Inc. ("PNP"), that grants GeoVax exclusive rights to develop and commercialize Gedeptin®, a novel patented product for the treatment of solid tumors.   The License provides exclusive worldwide rights to key intellectual property, including Gedeptin patents, know-how, regulatory fil

Continued Progress on COVID-19 and Immuno-Oncology Programs ATLANTA, GA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced its financial results for the quarter ended June 30, 2021. GeoVax's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time on Wednesday, August 11 to discuss financial results and provide a general business update. Details are provided below.   2021 YTD Highlights and Development Program Status Update COVID-19 Vaccine – GeoVax's SARS-CoV-2 (COVID-19) vaccine is b

Conference call to be held Wednesday, August 11, at 4:30 p.m. Eastern Time ATLANTA, GA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX) ("GeoVax" or the "Company"), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report second quarter 2021 financial results on Wednesday, August 11, 2021 after the market closes. Management will host a conference call at 4:30 p.m. ET on Wednesday, August 11, 2021 to review financial results and provide an update on corporate developments.  Following management's formal remarks, there will be a question and answer session. Partic

Additional Capital Raised to Support Acceleration ofCoronavirus and Immuno-Oncology Programs  ATLANTA, GA, May 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced its financial results for the three months ended March 31, 2021. GeoVax's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time on Thursday, May 6 to discuss financial results and provide a general business update. Details are provided further below. First Quarter 2021 Highlights Capital Resources– On February 11, 2021, GeoVax supplemente